Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected as documented by positive HIV antibody test~* Antiretroviral naïve~* Starting ARV prophylaxis from 28th weeks of gestation or at least 4 weeks before delivery~* Not intending to relocate out of the area for the duration of study participation~* Willingness of subject to adhere to follow up schedule (note: this is more intensive for the pilot PK phase)~* Ability and willingness of subject to give written consent~* Pregnant women aged 18 years and above~* Willing and able to regularly attend the antenatal clinic~Exclusion Criteria:~* Serious illness that requires systemic treatment or hospitalization~* Use of concomitant medication, which interferes with the ARV prophylaxis for PMTCT or phenytoin~* Any condition that in the opinion of the investigator would compromise the subjects' ability to participate in the study~* Previously treated for HIV infection with antiretroviral agents, including ARV prophylaxis for PMTCT~* Inability to understand the nature and extent of the trial and the procedures required~* CD4 count \<350 cells/µl because such a patient is eligible for HAART

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): ARV prophylaxis for PMTCT follows national guidelines.
- phenytoin interaction (Type: EXPERIMENTAL): ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).